Rubicon Research Limited has informed the Exchange about Investor Presentation

Rubicon Research reported strong Q4 FY26 results with revenue of ₹5,139 million, up 43.5% YoY, driven by broad-based growth in its US formulations business with ~98% USD-denominated revenue ($56 million in Q4). Full-year FY26 revenue stood at ₹17,540 million (up 36.6%) and PAT at ₹2,467 million (up 83.6%). The company acquired Arinna Lifesciences in April 2026 for ~₹176 crore (EV ₹200 crore, 85% stake), adding 60 CNS brands, 160 sales reps, and 4,000 active prescribers to build a domestic India formulations platform. Management flagged that near-term gross margins may compress slightly due to higher reliance on outsourced manufacturing, but guided that Operating EBITDA margin will sustain in the 22-23% range even in that scenario. Pithampur site inspection is awaited from USFDA with commercial ramp-up expected in Q1 CY27, which would be GM-accretive. R&D spend of ₹5,000 million+ is guided over 9 quarters (FY26 to Q1 FY28), with R&D productivity improving to 5.9x in FY26 vs 3.3x in FY24. Post-IPO, net debt reduced significantly from ₹3,932 million to ₹2,594 million. Board recommended dividend of ₹1.50 per share (10% payout).